Computational, Kinetics, and Corrosion Protection Aspects of Electrodeposited Poly(Salicylic Acid) Coatings as a Corrosion Inhibitor for Mild Steel

Poly(salicylic acid) PSA has been electrochemically deposited onto a Pt electrode. The kinetics of the polymerization reaction has been studied. The polymer structure was confirmed and characterized using IR spectroscopy, XRD, SEM, and TGA analysis. The deposited PSA was then collected from the Pt surface and tested as a corrosion inhibitor for a mild steel electrode in an aqueous medium of 1 M sulfuric acid. The corrosion behavior was then evaluated using potentiodynamic polarization and electrochemical impedance spectroscopy (EIS). Corrosion measurements showed that the inhibition efficiency of 20, 50, and 100 ppm of PSA was 33, 57, and 74%, respectively. The inhibition mechanism was proved using adsorption isotherms as well as quantum calculations. The inhibition of the corrosion process was due to the adsorption of PSA on the steel surface, which was found to comply with the Langmuir adsorption isotherm

International Nosocomial Infection Control Consortiu (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module

We report the results of an International Nosocomial Infection Control Consortium (INICC) surveillance study from January 2007-December 2012 in 503 intensive care units (ICUs) in Latin America, Asia, Africa, and Europe. During the 6-year study using the Centers for Disease Control and Prevention's (CDC) U.S. National Healthcare Safety Network (NHSN) definitions for device-associated health care–associated infection (DA-HAI), we collected prospective data from 605,310 patients hospitalized in the INICC's ICUs for an aggregate of 3,338,396 days. Although device utilization in the INICC's ICUs was similar to that reported from ICUs in the U.S. in the CDC's NHSN, rates of device-associated nosocomial infection were higher in the ICUs of the INICC hospitals: the pooled rate of central line–associated bloodstream infection in the INICC's ICUs, 4.9 per 1,000 central line days, is nearly 5-fold higher than the 0.9 per 1,000 central line days reported from comparable U.S. ICUs. The overall rate of ventilator-associated pneumonia was also higher (16.8 vs 1.1 per 1,000 ventilator days) as was the rate of catheter-associated urinary tract infection (5.5 vs 1.3 per 1,000 catheter days). Frequencies of resistance of Pseudomonas isolates to amikacin (42.8% vs 10%) and imipenem (42.4% vs 26.1%) and Klebsiella pneumoniae isolates to ceftazidime (71.2% vs 28.8%) and imipenem (19.6% vs 12.8%) were also higher in the INICC's ICUs compared with the ICUs of the CDC's NHSN